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ABSTRACT: Despite the well-known adverse health effects associated with
tobacco use, addiction to nicotine found in tobacco products causes difficulty in
quitting among users. Nicotinic acetylcholine receptors (nAChRs) are the
physiological targets of nicotine and facilitate addiction to tobacco products.
The nAChR-α7 subtype plays an important role in addiction; therefore, predicting
the binding activity of tobacco constituents to nAChR-α7 is an important
component for assessing addictive potential of tobacco constituents. We developed
an α7 binding activity prediction model based on a large training data set of 843
chemicals with human α7 binding activity data extracted from PubChem and
ChEMBL. The model was tested using 1215 chemicals with rat α7 binding activity
data from the same databases. Based on the competitive docking results, the
docking scores were partitioned to the key residues that play important roles in the
receptor−ligand binding. A decision forest was used to train the human α7 binding
activity prediction model based on the partition of docking scores. Five-fold cross
validations were conducted to estimate the performance of the decision forest models. The developed model was used to predict the
potential human α7 binding activity for 5275 tobacco constituents. The human α7 binding activity data for 84 of the 5275 tobacco
constituents were experimentally measured to confirm and empirically validate the prediction results. The prediction accuracy,
sensitivity, and specificity were 64.3, 40.0, and 81.6%, respectively. The developed prediction model of human α7 may be a useful
tool for high-throughput screening of potential addictive tobacco constituents.
■ INTRODUCTION
It has been established that the use of tobacco products is
harmful and causes deleterious health effects such as
respiratory disease, heart disease, multiple cancers, and many
other adverse effects on organ systems as detailed in the U.S.
Surgeon General Report.1,2 It is noted that tobacco use is the
most preventable cause of premature death in the United
States. However, 14.0% of all adults (34.3 million people:
15.8% of men and 12.2% of women) were current cigarette
smokers in 2017 (https://www.cdc.gov/vitalsigns/youth-
tobacco-use/?s_cid=osh-stu-home-slider-005). Also concern-
ing is that according to the CDC, in 2018, there were 4.9
million youth that used tobacco products, and in 2017−2018,
the use of any tobacco products grew by 38.3% among high
school students, and this increase can be attributed largely due
to the use of electronic cigarettes. These striking statistics
underscore the importance of better understanding nicotine
dependence; particularly how nicotinic acetylcholine receptors
(nAChRs), the physiological targets of nicotine, facilitate
addiction to tobacco products.
Nicotine dependence and reinforcement are mediated by a
family of pentameric ligand-gated ion channels, the nicotinic
acetylcholine receptors.3 Generally, the pentameric complex of
nAChRs consists of an extracellular domain or ligand binding
domain (LBD), a transmembrane region with four helices, and
an intracellular domain.4 The rodent neuronal and muscle-type
nAChR are the two-major types in the nAChR family. There
are various subunits reported for the neuronal nAChRs such as
α2−α10 and β2−β4. Among these subunits, α7−α10 are able
to form a homo-pentamer complex and the remaining subunit
α2−α6 forms heteromeric complexes by combining with
β2−β4.4−7 The α7 pentameric complex is highly present in the
human brain and plays an important role in addiction. Hence,
predicting the binding activity of tobacco constituents to
nAChR α7 is important for understanding the addictive
potential of tobacco constituents.8 More than 8000 chemicals
are identified in tobacco smoke.9 However, only a few tobacco
constituents have been tested for nAChR α7 binding activity.
Experimental evaluation of the remaining tobacco constituents
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is costly and time consuming. Well-established in silico
techniques such as molecular docking9−15 and machine
learning16−21 have been used for developing prediction models
of various biological activities. We previously applied molecular
docking and molecular dynamic simulations to reveal the
important residues of α7 nAChR that forms interactions with
tobacco constituents.22 In this study, we combined molecular
docking and machine learning to develop an α7 binding
activity prediction model based on a training data set of 930
chemicals with known human α7 binding activity data. Based
on the competitive docking results, the docking scores were
then partitioned to the key residues that play important roles in
the receptor−ligand binding. The developed model was used
to predict the potential human α7 binding activity for 5275
tobacco constituents.
This study presents a comprehensive assessment of tobacco
constituents that may exhibit addiction potential by binding to
the nAChR α7 receptors. The results from a validation test of
125 chemicals with known nAChR α7 receptor binding activity
indicate that prediction accuracy, sensitivity, and specificity
were 77.4, 57.7, and 86.2%, respectively. The development of a
prediction model of human α7 binding activity shows that
tobacco products may have unusually high proportions of
constituents relative to nicotine that may induce physiological
effects mediated through nAChR receptor subtypes.
■ MATERIAL AND METHODS
Study Design. The study design is depicted in Figure 1. In
brief, the human and rat α7 nAChR binding activity data were
curated from the public databases PubChem (https://
pubchem.ncbi.nlm.nih.gov/) and ChEMBL (https://www.ebi.
ac.uk/chembl/). The human and rat α7 nAChR binding
activity data were used as the training and external validation
data sets, respectively. The target set contains the tobacco
constituents that were curated from a publication.9 Com-
petitive molecular docking10 was used to generate the
descriptors. All chemicals of the three data sets were subjected
to competitive molecular docking to two-, three-dimensional
(3D) structures of human α7 nAChR constructed using
homology modeling and molecular dynamic (MD) simu-
lations. The resultant docking scores and the partitioned scores
to the residues in the active site of the 3D structures of α7
nAChR and their energy terms were used as the descriptors in
the model development. A decision forest algorithm21,23 was
used to generate the predictive model based on the training set.
The 5-fold cross validation was performed 1000 times to
determine the robustness and predictive power of the models.
In addition, the 5-fold cross validations were used to examine
the effect of prediction confidence and to identify the
important descriptors that indicate the key residues and their
interactions with ligands. The permutation was conducted to
estimate the predictivity of the model. The developed model
was validated using the external validation set of 1215
chemicals. The validated model was used to predict human
α7 nAChR binders or nonbinders for the tobacco constituents
from which 84 were selected to experimentally validate the
prediction results.
Data Sets. Training Data Set. The compounds with
human α7 nAChR binding activity data were collected from
the popular chemical databases PubChem and ChEMBL by
searching target CHRNA7. There were 803 and 974
compounds with human α7 nAChR binding activity data in
PubChem and ChEMBL, respectively. After removal of the
compounds that have a conflict with α7 nAChR binding
activity data between the two databases and the compounds of
which 3D structures could not be generated, 843 compounds
remained and were used as the training compounds. Based on
the α7 nAChR binding activity data, the 843 compounds were
classed as 715 binders and 128 nonbinders (Table S1). The
LigPrep module (https://www.schrodinger.com/ligprep) from
Maestro was used to generate the 3D structures of the 843
training compounds.
External Validation Data Set. The compounds, which had
rat α7 nAChR binding activity data, were collected from
PubChem and ChEMBL. In total, 1501 and 1512 compounds
were collected from PubChem and ChEMBL, respectively. In
the same way, the compounds with conflicted experimental
data and the compounds with difficulties to construct 3D
structures were discarded. The remaining compounds were
then classed into α7 nAChR binders and nonbinders using
their rat α7 nAChR binding activity data. The resultant 1290
binders and 122 nonbinders were used as the external
validation data set (Table S2). The 3D structures of the
compounds in the external validation set were generated using
LigPrep from Maestro.
Comparison of the training data set and the external
validation data set found 197 compounds in both data sets.
The 197 common compounds were removed from the external
validation data set. The remaining 1215 compounds were used
as the external validation data set (1096 binders and 119
nonbinders) to validate the model that was constructed using
the training data set.
Tobacco Constituents. It is documented that there are
more than 8000 tobacco constituents.9 The developed model
was used to predict the α7 nAChR binding activity of these
tobacco constituents. Three preprocessing steps were applied
to construct structures of these tobacco constituents. First,
8391 compounds with chemical abstracts service registry
numbers (CASNs) were extracted from public literature9 using
a Perl script. Second, the CASNs of 8391 compounds were
searched in the PubChem database to get the structural details.
Among the 8391 tobacco constituents, 6199 unique com-
Figure 1. Study design. Human and rat α7 nAChR binding data were
curated from PubChem and ChEMBL databases as training and
external validation sets. Tobacco constituents were taken from the
literature as the target set. Competitive docking was applied to all
three data sets, and the resulting docking scores were partitioned to
the amino acid residues near the binding pocket. The decision forest
algorithm was used to build the models in the 1000 iterations of 5-
fold cross validations. The model built with the entire training set was
externally validated and then used to predict α7 nAChR binding for
the target set.
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pounds were found in the PubChem database using the
CASNs. Finally, 5275 tobacco constituents remained after
removing the small inorganic compounds, mixtures, and ions.
The two-dimensional (2D) structures of 5275 tobacco
constituents were downloaded from PubChem. Molconvert
(https://chemaxon.com/marvin-archive/3.3.3/marvin/doc/
user/molconvert.html) was used to convert the 2D structures
into 3D structures with hydrogens. The LigPrep module from
Maestro was used to validate and minimize the 3D structures.
Competitive Molecular Docking. We previously con-
structed two 3D structures of human α7 nAChR using
homology modeling and MD simulations.22 They were used as
the target proteins for the molecular docking approach in this
study. Glide (www.schrodinger.com/Glide) from Maestro was
used to dock the compounds in the active site of the proteins.
First, a grid box was generated around the active site of each of
the two 3D structures of human α7 nAChR (hereafter, the two
structures are termed structure_1 and structure_2). The 3D
coordinates of the structure_ 1 and structure_2 are provided in
a pdb format in Tables S3 and S4. The compounds of the
training set and the external validation set, as well as the
tobacco constituents, were then docked inside the grid boxes
generated around the active sites of structure_1 and
structure_2 using the extra precision (XP) method. The
default docking parameters (0.80 for a van der Waals radius
scaling factor and a partial charge cutoff of 0.50 in the Glide
module) were applied. Five poses were selected for each pair of
the ligand and protein for subsequently post-docking
minimization. Of the five minimized poses, the best and its
docking score were output. The competitive docking yielded
three types of results: (1) the compounds were successfully
docked to one structure, structure_1 or structure_2; (2) the
compounds were successfully docked to both structures, the
structure with lower docking scores was selected for
subsequent analysis; (3) the compounds failed in docking to
both structure_1 and structure_2. The first and second types
of results assumed that the compounds are α7 nAChR binders,
and the third type of results indicated that the compounds are
α7 nAChR nonbinders.
Partition of Docking Scores. The overall docking score
for each complex was partitioned using its Glide output file to
the amino acid residues and energy terms. The energy terms
include hydrogen bonding, coulomb interaction, van der Waals
interaction, the sum of these three terms, and the minimum
distance between the ligand and residue. The residues within
12 Å from the grid center were used in the partitioning of the
overall docking scores. There are 14 residues from chain A
(148S, 149W, 150S, 151Y, 152G, 186R, 187F, 188Y, 190C,
192 K, 193E, 194P, and 195Y) and 23 residues from chain B
(32Y, 33F, 34S, 55W, 56L, 57Q, 58M, 59S, 60W, 77T, 79R,
107W, 108V, 109L, 110V, 111N, 115H, 116C, 117Q, 118Y,
119L, 120P, and 121P) within this space in α7 nAChR
structures (Figure 2) that were used in the partition.
Decision Forest Algorithm. A decision forest, a pattern
recognition algorithm we previously developed23 and applied
to analyze diverse types of data,17,20,26−28 was used to develop
the model to predict binders or nonbinders of human α7
nAChR for chemicals. The decision forest combines individual
trees to give final predictions based on the consensus of
predictions from the individual trees. More specifically, the
algorithm generated a decision tree based on the pool of
partitioned docking scores. The partitioned docking scores,
which were used in the previous tree, were then removed, and
the remaining pool of partitioned docking scores was used to
construct a new tree. The training result from combining all
trees was evaluated. This process was repeated until no
improvement in the training result could be achieved by
adding a new decision tree. The following parameters were
used to construct the individual trees: the maximum number of
trees was set to 5, the minimum size of the node to be split was
fixed at 10, the maximum number of levels to be pruned was 3,
and Gini’s diversity index was used for node splitting.
Performance Metrics. Seven prediction performance
metrics (sensitivity, positive predictive rate, specificity, negative
predictive rate, accuracy, Matthew’s correlation coefficient
(MCC), and balanced accuracy) were used to estimate
performance of the predictive models. The detailed calculation
equations for the seven metrics are provided in the Supporting
Information. These seven metrics measure different aspects of
a model. Sensitivity measures the capability of a model to
predict active chemicals, while specificity measures its
predictive capability on inactive chemicals. The positive
predictive rate and negative predictive rate indicate goodness
of positive and negative predictions for a model, respectively.
The accuracy measures the overall goodness of a model.
However, it depends at prevalence and biased to the training
majority. Balance accuracy and MCC reduce the dependency
of the overall performance of a model at prevalence.
Internal Validation. The 5-fold cross-validation approach
was used as the internal validation to validate the performance
of the model for predicting α7 nAChR binding activity. In a 5-
fold cross validation, the training data set was randomly
divided into five equal parts. Four parts were used to develop a
predictive model and the remaining one part was used to
validate the developed model. This process was repeated five
times so that each of the five parts was used once and only
once to challenge the model constructed using the other four
parts. The performance of the predictions was measured by
seven metrics calculated using all results of the five models.
The 5-fold cross validation was iterated for 1000 times to a
statistically robust performance estimation for the internal
validation.
External Validation. The performance of the developed
model using the decision forest was assessed using the external
validation data set. A decision forest model was first
constructed using the whole training data set. The model
Figure 2. Amino acid residues used in the partition. The top panel
gives the structures of human α7 nAChR constructed using templates
3SQ6 (left) and 2XYT (right). The proteins were drawn in the ribbon
model and the residues near the binding pockets in stick models. The
amino acids were listed separately for chain A and chain B in the
bottom panel.
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was then used to predict binders or nonbinders of α7 nAChR
for the chemicals in the external validation data set. The seven
metrics were calculated based on the prediction result to
estimate performance of the model.
Prediction Confidence Analysis. A multilabel classifica-
tion predictive model generated using the decision forest not
only predicts the class a sample belongs but also gives a
probability that estimates the confidence of the sample
belonging to the predicted class. Hence, the predictive model
could be evaluated not only using overall prediction perform-
ance metrics but also by prediction confidences of the
predictions. The prediction confidence from a decision forest
model is likely a value between 0 (least confident) and 1
(higher confident) that is calculated using the equation below
= | − |Pprediction confidence 0.5
0.5
where P is the prediction probability output from the decision
forest model.
The confidence levels of the predictions in the 5-fold cross-
validation were conducted to assess the performance of the α7
nAChR binding activity prediction model. First, the prediction
confidence values were calculated using the prediction
probability values for the predictions in the 1000 iterations
of 5-fold cross validation. The predictions were then assembled
into 10 groups based on their prediction confidence values that
were divided into 10 even bins. Lastly, the performance metrics
values were calculated separately for the predictions in those
10 groups. The relationship between the performance of
predictions and their prediction confidence levels was
analyzed.
Identification of Informative Amino Acids. The 1000
iterations of 5-fold cross-validation constructed 5000 decision
forest models that consists of tens of thousands of decision
trees. The frequency of a partitioned docking score in those
trees is an indication of the importance of the residue and
associated energy term. The higher the frequency the more
decision trees used the residue and the energy term. Analyses
of the frequency values of the partitioned docking scores were
Figure 3. Cross validation results. (A) Performance of the predictive model. The x-axis indicates performance metrics value and the y-axis gives the
frequency of the models with the performance among the 1000 iterations of 5-fold cross validations. (B) Prediction confidence analysis results. The
x-axis depicts the prediction confidence level. The number of predictions within a prediction confidence level from the 1000 iterations of 5-fold
cross validations was plotted as a black diamond indicated at the right y-axis, and the corresponding performance metrics were plotted as circles
(color codes in the color legend) with their values are indicated at the left y-axis. (C) The frequency of energy terms of amino acid residues of α7
nAChR where the x-axis gives the rank and the y-axis shows the frequency. (D) The top energy terms of amino acid residues in α7 nAChR. α7
nAChR was drawn in a ribbon model, the ligand in ball models, and the informative residues in a stick model. ACC: accuracy, SEN: sensitivity,
PPV: positive predictive value, SPE: specificity, NPV: negative predictive value, MCC: Mathews’ correlation coefficient, and BAC: balance
accuracy.
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conducted to identify the important amino acids that play key
roles in the interaction between ligands and α7 nAChR. We
first calculated the frequency values for all partitioned docking
scores. Then, the partitioned docking scores were ranked by
their frequency values, and a relative frequency was calculated.
The residues and interaction energy terms that had a relative
frequency greater than 1.5 in the decision forest (DF) models
in the 5-fold cross validations were more informative than
those with lower relative frequencies to the DF models.
Subsequently, the top partitioned docking scores (amino acids
and their energy terms) with a relative frequency greater than
1.5 were identified as informative descriptors that play key
roles in the binding of human α7 nAChR for chemicals.
Prediction of α7 nAChR Binding of Tobacco
Constituents. The predictive model that was constructed
using the whole training data set was used to classify the 5275
tobacco constituents as binders and nonbinders of human α7
nAChR. To assess the reliability of the prediction results of the
5275 tobacco constituents, 84 were randomly selected to be
experimentally validated using the previously developed assays
after considering compounds availability and similar distribu-
tion of predictions.25 The 84 experimentally tested tobacco
constituents and their measured activity values are given in
Table S5.
Here, a brief description of the assay is given. The nAChR
α7 was expressed in Chinese Hamster Ovary (CHO) cell lines
as described previously.24 The CHO cells were maintained in
Ham’s F-12 media and transfected with the linearized cDNA
constructs by nucleofection. The transfected cells were
incubated with α7/RIC3 (antibiotics) for 2 weeks to select
the stably expressed cells. The transfected cells were passed to
the medium lacking antibiotics before 2 to 4 days to start the
experiment. The test chemicals were dissolved in dimethyl
sulfoxide (DMSO) and prepared in 384-well compound plates
using an automated liquid handling system. Then, the cell
suspension was added into the wells, and membrane currents
were recorded by on-board patch clamp amplifiers. Inward
current peak amplitudes and charge movement were measured.
The α7 nAChR activation was calculated as the ratio of the
agonist-elicited current signal to the mean current signal
elicited with 300 μM nicotine.
Generation of Chemical Space. To better understand
the performance of the model, the chemical spaces of the
training chemicals, the chemicals in the external validation set,
and the tobacco constituents were generated. First, the
partitioned docking scores for each of the three sets of
chemicals were transformed by principal component analysis
using MatLab (https://www.mathworks.com/products/
matlab.html). Then, the top three principal components
were used to present the chemical spaces. At last, the three
chemical spaces were visually compared using scatter plots.
■ RESULTS
Internal Validation. One thousand 5-fold cross validations
were conducted to estimate the robustness and accuracy of the
models generated for predicting of human α7 nAChR binding
activity of chemicals. The performance metrics values of the
models from the 5-fold cross validations were calculated and
are given in Figure 3A. The average predicted accuracy,
sensitivity, specificity, MCC, and balanced accuracy values for
1000 times iteration of 5-fold cross validation are 0.831, 0.883,
0.541, 0.395, and 0.712, respectively. The metric values
indicated that the predictive model has an excellent predictive
power to differentiate the binder and nonbinder of human
nAChR.
Prediction Confidence. The prediction confidence was
analyzed for the predictions from the 1000 iterations of 5-fold
cross validation. Figure 3B shows the accuracy, sensitivity,
specificity, balanced accuracy, and MCC calculated for the
predictions against their prediction confidence. It was observed
that performance of predictions is dependent at their
prediction confidence: the higher likelihood value in a
prediction, the better is the performance of the prediction.
For the predictions with confidence higher than 0.8, the
accuracy is higher than 90%. Furthermore, most of the
predictions were at the middle (0.3−0.7) or high (>0.7)
confidence level. The prediction confidence analysis demon-
strated the prediction confidence from the models provides an
additional parameter that facilitates the application of the
human α7 nAChR binding activity prediction model.
Identification of Key Amino Acids. The amino acids and
their energy terms that are important to human α7 nAChR
binding were selected based on the frequency of the
descriptors used in the predictive models generated in the
1000 iterations of 5-fold cross validations. Figure 3C plots the
ranked amino acid energy terms against the frequency used in
the decision trees. The average frequency of all residue energy
terms was calculated. The relative frequency (frequency
divided by the average frequency) was calculated for each
amino acid energy term. The energy terms with a relative
frequency greater than 1.5 (used in >54,500 trees) were
deemed more informative than those with lower relative
frequencies to the DF models. Of the 186 amino acid energy
terms used in the constructions of the human α7 nAChR
predictive models in the cross validations, 28 were used by
more than 54,500 decision trees and are from 14 amino acids.
Among the 14 amino acids, L119 and C193 were reported to
form interactions with nicotine.29 The key amino acids and
their energy terms identified by the 5-fold cross validations in
the complex structure of the human a7 nAChR with
CHEMBL1835619 are depicted in Figure 3D. The site-
directed mutagenesis studies found that the mutations of
glycine 189 of the chicken α7-subunit to aspartic acid, glutamic
acid, asparagine, and glutamine impacted neonicotinoid
sensitivity of the α7 nAChR.30 Interestingly, this glycine is
not in the list of key amino acids identified in our modeling.
This may indicate that this smallest residue may not directly
interact with ligands but is in the binding region. Mutation of it
to a bulkier amino acid changes the conformation of its
adjacent residues (the key amino acid proline 121 identified in
this study) that in turn affect interactions with ligands.
However, the evident interaction mechanism of this glycine
deserves further investigation.
External Validation. Table 1 summarizes the prediction
results of an external test set (1215 chemicals with rat α7
Table 1. Validation Results of the Predictive Model
validation
results actual
predicted
positives
predicted
negative total
external positives 962 134 1096
negatives 99 20 119
total 1061 154 1215
experimental positives 14 21 35
negatives 9 40 49
total 23 61 84
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nAChR binding experimental data) using the human α7
nAChR binding predictive model. The accuracy, sensitivity,
specificity, balanced accuracy, MCC, positive predictive rate,
and negative predictive rate for the external test set are 0.808,
0.878, 0.168, 0.523, 0.132, 0.907, and 0.130, respectively. The
external validation results confirmed the predictive power of
the human α7 nAChR binding predictive model.
Prediction on Tobacco Constituents. The 5275 tobacco
constituents were docked in the binding sites of homology-
modelled human α7 nAChR, structure_1 and structure_2,
based on two template structures. Among the 5275 tobacco
constituents, 5132 were successfully docked in the binding site
of structure_1 or structure_2. The remaining compounds
failed to dock in the binding site of structure_1 or structure_2.
The docking scores were partitioned in different energy terms
to the residues (12 Å from the center of the grid) in the
binding sites of structure_1 and structure_2. The human α7
nAChR binding predictive model was used to identify the
binders and nonbinders of human α7 nAChR from 5132
tobacco constituents. Among the 5132 tobacco constituents,
1597 were predicted as binders and 3535 were predicted as
nonbinders of the human α7 nAChR (Figure 4). The
prediction confidence analysis was calculated for the 1597
predicted binders. Among the 1597 binders, 13 tobacco
constituents showed a higher confidence value (greater than
0.6), 112 had prediction confidence values between 0.3 and
0.6, and the remaining 1272 had low prediction confidence
values less than 0.3.
Validation of Prediction Results. To confirm the
predictive power and robustness of the human α7 nAChR
binding predictive model, 84 tobacco constituents were
randomly selected to experimentally test for human α7
nAChR binding. Among the 84 compounds, 23 and 61 were
predicted as binders and nonbinders, respectively (Table S5).
The experimental validation of the 84 tobacco constituents
showed that 35 and 49 compounds were binders and
nonbinders of human α7 nAChR, respectively. The compar-
ison between the experimental and prediction results is
summarized in Table 1. The prediction accuracy, sensitivity,
specificity, balanced accuracy, MCC, positive prediction rate,
and negative prediction rate for the 84 compounds were 64.3,
40.0, 81.6, 60.8, 23.9, 60.8, and 65.5%, respectively.
■ DISCUSSION
Knowing the 3D information of a target protein has the
potential to improve the predictive model for ligand binding to
the target. Understanding the interactions between tobacco
constituents and residues in the binding site of human α7
nAChR is important to identify its potential binders and
nonbinders given the role in nicotine addiction that this target
protein plays. Until now, a 3D structure of human α7 nAChR
was not available. Hence, homology modelling methodology
was used to generate the 3D structures of human α7 nAChR
based on two templates. The template proteins were selected
based on the binding pocket of the AChR.
Molecular docking is one of the well-known methods to
estimate binding potential in the binding site of a protein for
chemicals. Rigid and flexible docking methods are widely used
by researchers. Rigid docking does not allow flexibility for the
protein. Flexible docking gives flexibility to the protein;
however, it is time consuming to run flexible docking.
Hence, it is difficult to apply flexible docking in the screening
of a large number of compounds, such as those that are known
to be present as constituents in tobacco smoke. To overcome
this difficulty, more than one experimentally determined 3D
structures of a protein are used in molecular docking. Hence,
the competitive docking method was developed previously10,22
and used to dock the compounds in the binding site of human
α7 nAChR in this study to accommodate the conformations
induced by chemical binding.
In this investigation, the predictive model was developed
based on the binding data set of the human α7 nAChR. The
predictive model was validated using rigorous cross-validation
and external validation test sets. However, it should be noted
that the human α7 nAChR binding predictive model has
limitations when it is applied to assess addiction potential for
tobacco constituents. One limitation is due to the inaccurate
descriptors generated based on the homology models of the
human α7 nAChR optimized using molecular dynamics
simulations. Hence, using experimentally determined crystal
structures of the human α7 nAChR could improve the human
α7 nAChR predictive model. Another limitation is caused by
the imbalance of binders and nonbinders in the training set.
The training set contains a higher number of binders (85%)
than nonbinders (15%). Consequently, as demonstrated in the
cross-validation and external validation tests, the model
performed with a higher skill in the prediction of binders
than nonbinders. Therefore, the model has a limitation in its
prediction of specificity. Inclusion of more negative com-
pounds in the training data set is expected to improve the
specificity of the predictive model. However, the high level of
sensitivity that was observed based on external validation with
rat α7 nAChR binding activity data that were collected from
PubChem and ChEMBL for a robust set of 1215 chemicals
(>80%) is promising. From a public health and knowledge
development standpoint of identifying the harm of compound
addiction liability, being able to predict a tobacco constituent,
ingredient, or additive to bind to the nAChR is advantageous.
The advantage of a high sensitivity performing predictive
model is that the model would tend to error on the side of
predicting a false positive rather than a false negative. For
obvious reasons of protecting public health from addiction,
erroring on the side of a false positive is more desirable than a
false negative. Additionally, a highly sensitive model supports
efforts with compound priority setting for further testing to
confirm the ligand−protein interaction. Therefore, the model
higher sensitivity compared to high specificity is a desirable
performance characteristic from a regulatory perspective.
A model is trained by extracting the relationship among the
chemicals in the training set. Therefore, the chemical space of
Figure 4. Predictions on α7 nAChR binding activity for the tobacco
constituents. The types of the predictions were given by the slices of
the pie. Predicted α7 nAChR nonbinders are color coded in blue, high
confidence binders in purple, moderate confidence binders in green,
and low confidence binders in red. The number of tobacco
constituents is given for each slice.
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the training chemicals is important for suitable applications of
the model. If the chemicals in prediction are not covered and
far away from the training chemical space, the model is not
suitable for the prediction and the prediction results may not
be reliable. The chemical space of the training set, test set, and
the target tobacco constituents was calculated using PCA
based on Mold2 descriptors.31 The chemical spaces shown in
Figure S1 revealed that the chemical training space of the
model covered most of the chemicals in the test set the
tobacco constituents in the prediction. Therefore, the
prediction results on the tobacco constituents are expected
to be useful. Moreover, the chemical coverage for the test set
and tobacco constituents are similar, and the performance of
the prediction results on the tobacco constituents is close to
the external validation performance.
Comparison of the training set with the external test set
found that 197 compounds have been tested for both human
and rat α7 nAChR. Hence, the 197 compounds were used to
estimate the consistency between the experimental data of
human and rat α7 nAChR. The consistency was used to assess
the performance of the predicted model that was generated
based on human α7 nAChR assay data on the compounds
tested with rat α7 nAChR assay data. Among 197 compounds
tested in human α7 nAChR had shown 167 and 0 compounds
as positive and negative, respectively, in rat α7 nAChR. The
metrics such as accuracy, sensitivity, specificity, balanced
accuracy, MCC, and positive and negative prediction rate
values are similar with those from external validation results
(Table 1), indicating that the developed model reached the
performance of experiments.
Prediction confidence analysis showed that the human α7
nAChR predictive model can accurately predict the binding
activity for most compounds but not so well for some
compounds. Increase in the prediction confidence value
improves the prediction accuracy. Hence, combining the
activity prediction by the human α7 nAChR predictive model
with its prediction confidence analysis could better utilize the
prediction results.
Although in product development efforts, there may be a
focus on generating a model that performs with a high positive
predictivity rate (i.e., models with high specificity),32,33 it is
also within reason to support strategies in tobacco harm
reduction using a predictive model geared toward a high
negative predictive value (i.e., models with high sensitivity),
which is a metric that indicates how frequent negative
predictions are correct. False negatives may be a great concern
for regulatory purposes because there is an addiction liability
associated with binding to the human α7 nAChR, and a
prediction that tends to make erroneous negative predictions
(i.e., high false negative rate) would miss detecting this liability.
Models with high specificity have high false negative rates, and
although models with high sensitivity have high false positive
rates, an error in prediction with a high sensitivity performing
model, such as the one in this study, would side on ensuring
that there is predictive power in detecting the potential harm
of binding to the human α7 nAChR. The 5-fold cross
validations and external validation showed higher sensitivity
than specificity, which is a favorable observation in predictive
performance for regulatory science. Although the model needs
improvement in specificity, the high sensitivity is highly
promising and makes it more suitable for screening of positives
than predicting negatives. As a model development strategy,
this study not only undertook a thorough computational cross
validation through performing 1000 iterations in the cross-
validation test but it also performed external validation using
randomly selected test set of compounds with known activity
to bind to human α7 nAChR. The external validation
assessment then went even further to learn of the model
predictive performance. From a structure−activity and
structure−property relationship with respect to nAChR
alpha7, it appears that the nAChR alpha receptor has
marginal-to-good specificity for this test set given that 30%
(1597 of 5275) of the modeled tobacco chemicals bind to the
receptor, and the chemical space of the model showed a good
coverage of the chemicals. Yet, only 13 tobacco constituents
showed a higher confidence value (greater than 0.6), and 112
had prediction confidence values between 0.3 and 0.6, with the
remaining 1272 showing low prediction confidence values (<
0.3). It performed an additional layer of external validation by
conducting experimental testing of a subset of the external
validation test set to verify binding or nonbinding activity to
the human α7 nAChR. Thus, there was extensive validation
and rigorous testing of the model that provides evidence on
how we could expect the model to perform. Since high
sensitivity was a characteristic feature of the predictive
performance of the model during validation tests, there is
utility for it in screening tobacco constituents for their
potential to contribute to addiction liability of tobacco
products.
Among the 186 amino acid energy terms used in the models,
28 were identified as informative descriptors to the human α7
nAChR predictive models (Figure 3D). Therefore, these
residues and their interaction energy terms are considered as
the most important structural features to differentiate the
binder and nonbinder of human α7 nAChR for tobacco
constituents based on their interactions with the human α7
nAChR. The 28 structural features of the human α7 nAChR
are expected to help in understanding the binding interactions
of tobacco constituents with human α7 nAChR.
■ CONCLUSIONS
In this study, the human α7 nAChR predictive model was
developed and extensively validated using large data sets
collected from the public chemical databases as well as
experimental testing post computational prediction. The
competitive docking method used in this study revealed the
important residues and their energy terms involved in the
binding of the compounds in the binding site of human α7
nAChR. The results obtained from the competitive docking
were used as descriptors to build a predictive model using the
decision forest algorithm to differentiate tobacco constituents
as potential binders or nonbinders to the human α7 nAChR.
The 1000 iterations of 5-fold cross-validation and permutation
tests confirmed that the predictive model has good predictive
ability and robustness. The predictive power of the model was
further demonstrated by the external validation testing. The
validated predictive model was used to differentiate the binder
and nonbinder for the tobacco constituents. The predictive
performance of the human α7 nAChR predictive model on the
tobacco constituents was experimentally validated on the
randomly selected 84 tobacco constituents. In addition, the
prediction confidence from the model provides information on
the utilization of the prediction results. In conclusion, the
developed predictive model for ligand binding to the human
α7 nAChR demonstrated a performance with utility for
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screening tobacco constituents for harm with regard to
potential addiction liability.
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